
LSP, Andera et al. invest €116m in AM-Pharma
New investors LSP and Andera Partners have joined existing backers to inject €116m into Netherlands-based AM-Pharma, a clinical-stage biopharmaceutical company.
Existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare also took part in the round.
Proceeds will be used for the 1,400-patient international pivotal phase-III trial of recombinant human alkaline phosphatase (recAP) in patients with sepsis-associated acute kidney injury (AKI).
The company is backed by venture capital funds and corporate venture funds, and has raised €195m in equity and debt to date, according to a statement.
Previous funding
AM-Pharma completed a first financing round in 2001, gathering a total of €640,000 from management, private investors and BioPartner Startup Ventures, a venture fund supported by the Dutch Ministry of Economic Affairs.
Inventages and ABN Amro Life Sciences Capital provided AM-Pharma with €6m and €3m respectively in 2005. Two years later, Forbion and Inventages contributed €2.5m to the biotech and in 2008 injected €7m. At the time, AM-Pharma was making preparations for a potential IPO, and Forbion owned a large minority stake in the company, Unquote previously reported.
It then raised €29.2m from Ysios, KLS, BB Biotech, Forbion, Idinvest and Inventages in 2011. Ysios and KLS led the round, with the former contributing €4.5m in capital.
Three years later, Gilde and existing investors injected a further €12.2m funding.
Company
AM-Pharma is a clinical stage biopharmaceutical company developing treatment for AKI with its drug recAP. AKI has a high mortality rate and no approved pharmacological treatments. The most prominent cause of AKI, which affects millions of patients worldwide, is sepsis.
Founded in 2001, the business is based in Bunnik.
People
AM-Pharma – Erik van den Berg (CEO).
LSP – Martijn Kleijwegt (managing partner).
Andera Partners – Raphaël Wisniewski (partner).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater